Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 5, 2000, Pages 1783-1788

  Downs Jr , Robert W ^a   Bell, Norman H ^b   Ettinger, Mark P ^c   Walsh, Brian W ^d   Favus, Murray J ^e   Mako, Barbara ^f   Wang, Lixia ^f   Smith, Mary E ^f   Gormley, Glenn J ^f   Melton, Mary E ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Clin Res Center of South Florida   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITONIN; CALCIUM CARBONATE; SALCATONIN;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NOSE IRRITATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCITONIN; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PLACEBOS;

EID: 17744372118     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.5.1783     Document Type: Article

References (16)

1. Therapeutic controversy: Hormone replacement therapy - Where are we going?
2. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis
3. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
4. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
5. Nasal calcitonin for treatment of established osteoporosis
6. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
7. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
8. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
9. Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake
10. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: Three-year interim results of the PROOF study
11. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group
12. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin
13. Treatment of osteoporosis in postmenopausal women: Alendronate vs. intranasal calcitonin
14. Treatment of osteoporosis in postmenopausal women: Alendronate vs. intranasal calcitonin